Early Trial Shows Gene Editing Therapy Significantly Lowers Blood Fat Levels

A Phase 1b clinical trial by Cleveland Clinic found that the CRISPR-Cas9 gene-editing therapy, CTX310, dramatically reduced triglyceride levels in patients with severe hypertriglyceridemia. Participants experienced an average 63% reduction in triglycerides and over 65% drop in ANGPTL3 levels 30 days post-infusion. This treatment targets the ANGPTL3 gene, a key lipid metabolism regulator, offering potential long-lasting benefits for heart disease and pancreatitis risk, though further research is needed.